Needham & Company LLC reissued their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Monday, Benzinga reports. They currently have a $11.00 price target on the stock.
A number of other equities research analysts have also weighed in on the company. Wedbush reaffirmed an outperform rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Monday, May 13th. HC Wainwright reaffirmed a buy rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 4th. Finally, BTIG Research started coverage on TScan Therapeutics in a research report on Thursday, May 16th. They issued a buy rating and a $12.00 price target for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $12.00.
Get Our Latest Analysis on TCRX
TScan Therapeutics Trading Down 1.7 %
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.07). The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $3.75 million. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. As a group, sell-side analysts predict that TScan Therapeutics will post -1.25 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in TCRX. Dimensional Fund Advisors LP bought a new position in shares of TScan Therapeutics in the 2nd quarter worth $70,000. Pale Fire Capital SE increased its position in TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after buying an additional 4,998 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in TScan Therapeutics during the 2nd quarter valued at about $134,000. Cannon Global Investment Management LLC acquired a new position in TScan Therapeutics during the 1st quarter valued at about $139,000. Finally, Rhumbline Advisers acquired a new position in TScan Therapeutics during the 2nd quarter valued at about $274,000. 82.83% of the stock is owned by institutional investors.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Read More
- Five stocks we like better than TScan Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Small Cap Stocks Insiders Are Actively Buying
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Market Turbulence: Time to Snap Up Magnificent Seven Stocks?
- Dividend Payout Ratio Calculator
- Buy the Dip in Home Depot, But Wait for It to Bottom First
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.